Gyomor- és nyelőcsőrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• HER2 84
• PD-1 108
• PD-L1 49
• CLDN18 35
• TP53 1
• PI3K 1
• AKT 1
• STAT3 1
• mTOR 0
• CTNNB1 0
• VEGF 7
• YAP 0
• MAPK 0
• EGFR 10
• ERK 0
• FGFR 1
• JAK 0
• HIF-1 0
• MYC 0
• PTEN 3
• CTLA-4 8
• NRF2 0
• MET 5
• STING 0
• CXCR4 0
• B7-H3 6
• JNK 0
• AMPK 0
• GPX4 0
• TROP2 6
• IL-6 0
• METTL3 0
• COX-2 0
• KRAS 2
• ARID1A 1
• BRCA1 2
• FAK 0
• LAG-3 0
• MDM2 0
• MMP-9 0
• PARP 0
• PPAR 0
• TIGIT 1
• BRCA2 1
• HSP90 0
• BCL-2 0
• FTO 0
• SHP2 0
• BRAF 0
• CD47 1
• CDK4/6 0
• HDAC 0
• HER3 3
• HMGB1 1
• MEK 0
• PDGFR 2
• TIM-3 0
• TNF 0
• ATM 0
• AXL 2

2590 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-RIA

  IMproving the outcome of Peritoneal and Pleural metastases using Aerosolized ChemoTherapy (IMPACT)

  Universiteit Gent· Gent, Belgium· EU contribution 10 031 371 EUR· until 2032. jún.· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Spatial profiling of gastric cancer with peritoneal carcinomatosis to tackle cancer spreading and improve precision immuno-oncology (SPARC)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 236 340 EUR· until 2028. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Dissecting chromosomal instability in gastric cancer and its role in immunoediting using advanced functional and multiplexed single cell sequencing technologies (CINbyFUNseq)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Hollandia· EU contribution 2 000 000 EUR· until 2030. márc.

• European Commission (Horizon Europe) · HORIZON-EIC

  Hybrid endoscope for esophageal in vivo histology and histochemistry (ESOHISTO)

  Medizinische Universitaet Wien· Wien, Ausztria· EU contribution 3 643 628 EUR· until 2029. jan.· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  In vivo Immunofluorescence-Optical Coherence Tomography (Immuno-OCT)

  Stichting Vu· Amsterdam, Hollandia· EU contribution 2 500 000 EUR· until 2029. dec.

  The disease is named only in the funder's project summary, not in the title.

5 of 10 running projects, newest first. Listed amounts together: 38,7 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

  NCT03604991· National Cancer Institute (NCI)· Frissítve: 2026. nov. 12.

  “End of Initial Phase of Multi-phase protocol”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

  NCT05075993· M.D. Anderson Cancer Center· Frissítve: 2026. nov. 10.

  “\<75% participation”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

  NCT05911243· University of Washington· Frissítve: 2026. nov. 3.

  “Study closed per SRC Low Accrual Policy.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Adaptive Radiation for Abdominopelvic Metastases

  NCT05880667· Fox Chase Cancer Center· Frissítve: 2026. nov. 2.

  “Pending interim analysis”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  HEARTS Trial for Thoracic Cancers

  NCT07132918· University of Wisconsin, Madison· Frissítve: 2026. okt. 30.

  “Funding issues”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

  NCT04111172· Thomas Jefferson University· Frissítve: 2026. okt. 28.

  “Protocol is with FDA review, waiting for funding to be released”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Frissítve: 2026. okt. 26.

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Non-endoscopic EC Screening Program in Northern Iran

  NCT02311712· Tehran University of Medical Sciences· Frissítve: 2026. okt. 16.

  “Waiting to receive capsule sponge device from the manufacturer.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Proton Beam Therapy in the Treatment of Esophageal Cancer

  NCT03482791· Washington University School of Medicine· Frissítve: 2026. okt. 2.

  “The study is no longer relevant to have open to ensure insurance approval for this patient population”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  RCT of Mobile Apps & FitBit v. Usual Care

  NCT03623464· Weill Medical College of Cornell University· Frissítve: 2026. szept. 28.

  “Study is paused for interim analysis.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  NCT01950572· National Cancer Institute (NCI)· Forrás

• Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  NCT06203600· National Cancer Institute (NCI)· Forrás

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Forrás

• Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

  NCT04907643· Cedars-Sinai Medical Center· Forrás

• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

  NCT04704661· National Cancer Institute (NCI)· Forrás

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Forrás

• Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07933471· Beijing Tsinghua Chang Gung Hospital· Forrás

• Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

  NCT03030404· National Cancer Institute (NCI)· Forrás

• Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

  NCT03604991· National Cancer Institute (NCI)· Forrás

• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

  NCT04491942· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 71
• Organoids 34
• Mendelian Randomization Analysis 42
• CRISPR-Cas Systems 9
• Gene Expression Profiling 198
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 8
• Exome Sequencing 14
• Proteomics 55
• Metabolomics 42
• Mass Spectrometry 5
• Flow Cytometry 33
• Immunohistochemistry 151
• Liquid Biopsy 18
• Circulating Tumor DNA 25
• Xenograft Model Antitumor Assays 288
• Positron-Emission Tomography 22
• Magnetic Resonance Imaging 24
• Machine Learning 133
• Deep Learning 65
• Cohort Studies 175
• Genome-Wide Association Study 48

• Integrative hdWGCNA and Machine-Learning Analysis Identifies Gastric Cancer Candidate Genes and Supports a Functional Role for KRT18.

  J Vis Exp, 2026. nov.

• Integrated bulk and single-cell transcriptomics with virtual knockout analysis identifies FOS as an epithelial-associated candidate gene in chronic atrophic gastritis.

  Funct Integr Genomics, 2026. okt.

• Single-cell analyses reveal lymph node-tumor ecosystem remodeling during lymph node metastasis of gastric cancer.

  Cell Rep, 2026. okt.

• Single-cell transcriptomics reveals a complex cell-cell communication network driven by myofibroblast-derived collagen in esophageal squamous cell carcinoma.

  Cancer Lett, 2026. szept.

• Early diagnosis and molecular classification of gastric cancer peritoneal metastasis by deep learning-driven single-cell lipidomics.

  Cell Rep Med, 2026. szept.

• D2O-Labeled Single-Cell Raman Spectroscopy Reveals the Evolutionary Trajectory of Helicobacter pylori During the Phenotypic Silent Window.

  Small Methods, 2026. szept.

• Exploration and experimental verification of triaptosis-related prognostic genes and cells in gastric cancer.

  Mol Biol Rep, 2026. szept.

• Case Report: Single-cell transcriptomic profiling of a pediatric ALK-negative gastric inflammatory myofibroblastic tumor.

  Front Immunol, 2026. aug.

• DBP: Adaptive and Interpretable Factor Analysis for Single-cell RNA-seq Data with Deep Beta Processes.

  Genomics Proteomics Bioinformatics, 2026. aug.

• Single-cell and spatial landscape reveals impaired tertiary lymphoid structure maturation in Helicobacter pylori-associated gastric cancer.

  Front Immunol, 2026. aug.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.